---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-115985"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T06:26:16.671266+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Ironwood Q3 total revenue $113.7M, GAAP diluted EPS $0.09 vs $0.28 YoY

## Summary
- Total revenues $113.7M (up 5% YoY); GAAP net income $15.3M, diluted EPS $0.09 vs $0.28.
- LINZESS U.S. net sales $279M (+7% YoY); prescription demand +8%.
- Positive final data from Phase II STARS Nutrition study of apraglutide in SBS-IF with CIC.
- Expects topline data for CNP-104 in primary biliary cholangitis in Q3 2024.
- Maintains full year 2023 guidance.

## SEC filing metadata
- accession: 0001104659-23-115985
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465923115985/0001104659-23-115985-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465923115985/tm2330146d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-115985
- JSON: https://secwatch.observer/filing/0001104659-23-115985.json
- Plain text: https://secwatch.observer/filing/0001104659-23-115985.txt

## Key facts
- Earnings Releases
  IRONWOOD PHARMACEUTICALS INC reported the quarter ended September 30, 2023 results: revenue Total revenues $ 113,739 $ 108,637, net income GAAP net income 13,950 50,317, EPS GAAP net income attributable to Ironwood Pharmaceuticals, Inc. per share – diluted 0.09 0.28. Guidance reaffirmed.
  - Period: the quarter ended September 30, 2023
  - Revenue: Total revenues $ 113,739 $ 108,637
  - Net income: GAAP net income 13,950 50,317
  - EPS: GAAP net income attributable to Ironwood Pharmaceuticals, Inc. per share – diluted 0.09 0.28
  - Guidance: reaffirmed
  - Result: reported results
  source text: the year and meaningful pipeline catalysts ahead in 2024.” Third Quarter 2023 Financial Highlights 1 (in thousands, except for per share amounts) Q3 2023 Q3 2022 Total revenues $ 113,739 $ 108,637 Total operating expenses 73,716 40,164 GAAP net income 13,950 50,317 GAAP net income attributable to Ironwood Pharmaceuticals, Inc. 15,321 50,317 GAAP net income
  evidence_url: https://www.sec.gov/Archives/edgar/data/1446847/000110465923115985/0001104659-23-115985-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.